Core Viewpoint - Aojing Medical announced the appointment of Qiu Zhiye as the company's secretary of the board on November 26 [1] Group 1 - Aojing Medical made an official announcement regarding the new appointment [1]

奥精医疗科技股份有限公司 证券代码：688613 证券简称：奥精医疗 公告编号：2025-063 关于选举第三届董事会职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 奥精医疗科技股份有限公司（以下简称"公司"）于2025年11月10日召开第二 届董事会第十七次会议，并于2025年11月26日召开2025年第三次临时股东大会， 审议通过了《关于取消监事会、增加注册资本并修订〈公司章程〉的议案》。 根据修订后的《奥精医疗科技股份有限公司章程》（以下简称"《公司章程》"）， 公司第三届董事会由9名董事组成，其中1名职工代表董事，由公司职工通过职 工代表大会选举产生。 公司于2025年11月26日召开2025年第一次职工代表大会，选举Helen Han Cui（崔菡）为公司第三届董事会职工代表董事（简历详见附件），将与公司股 东大会选举产生的5名非独立董事、3名独立董事共同组成公司第三届董事会， 任期三年，自本次职工代表大会审议通过之日起至第三届董事会届满之日止。 上述职工代表董事符合《公司法》等相关法律法规和 ...

证券代码： 688613 证券简称：奥精医疗 公告编号：2025-064 奥精医疗科技股份有限公司 关于完成董事会换届选举及聘任高级管理人员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上海证券 交易所科创板股票上市规则》（以下简称"《科创板上市规则》"）、《上海证 券交易所科创板上市公司自律监管指引第 1 号——规范运作》等法律、法规、 规范性文件及《奥精医疗科技股份有限公司章程》（以下简称"《公司章程》"） 等有关规定，奥精医疗科技股份有限公司（以下简称"公司"）于2025年11月26 日召开2025年第三次临时股东大会，选举产生了公司第三届董事会非独立董事 （不含职工代表董事）和独立董事，并与公司职工代表大会选举产生的职工代表 董事，共同组成公司第三届董事会。 公司于2025年11月26日召开第三届董事会第一次会议，审议通过了《关于 选举第三届董事会董事长的议案》《关于选举第三届董事会各专门委员会委员的 议案》《关于聘任公司总经理的议案》《关于聘任公 ...

2025年第三次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 证券代码：688613 证券简称：奥精医疗 公告编号：2025-062 奥精医疗科技股份有限公司 （二） 股东大会召开的地点：北京市大兴区庆丰西路 69 号 35 号楼 3 层 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 49 | | --- | --- | | 普通股股东人数 | 49 | | 2、出席会议的股东所持有的表决权数量 | 27,904,066 | | 普通股股东所持有表决权数量 | 27,904,066 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 20.3666 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 20.3666 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次会议由公司董事会召集，董事长 Eric Gang Hu 未出席，过半数董事按章程 选举董事黄晚兰主持。会议采用现场投票和网络投票相结 ...

法律意见书 北京市中伦律师事务所 关于奥精医疗科技股份有限公司 2025 年第三次临时股东大会的 法律意见书 致：奥精医疗科技股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受奥精医疗科技股份有限公 司（以下简称"公司"）委托，指派律师见证公司 2025 年第三次临时股东大会 （以下简称"本次股东大会"）。本所律师根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）、《律师事务所从事 证券法律业务管理办法》等相关法律、法规、规章、规范性文件及《奥精医疗科 技股份有限公司章程》（以下简称"《公司章程》"）的规定，对本次股东大会 的相关事项进行见证并出具法律意见。 为出具本法律意见书，本所律师审查了公司本次股东大会的有关文件和材料。 本所律师出具本法律意见书基于公司向本所律师提供的一切原始材料、副本、复 印件等材料、口头证言均是真实、准确、完整和有效的，不存在隐瞒记载、虚假 陈述或重大遗漏，有关文件的印章和签字均真实、有效，有关副本、复印件等材 料均与原始材料一致。 1 在本法律意见书中，本所律 ...

Core Insights - On November 21, Aojing Medical experienced a decline of 5.33% with a trading volume of 71.50 million yuan [1] - As of November 21, the total margin balance for Aojing Medical was 172 million yuan, representing 6.49% of its market capitalization [1] Financing Summary - On November 21, Aojing Medical had a financing buy-in amount of 6.40 million yuan and a financing repayment of 6.40 million yuan, resulting in a net financing buy of -4946 yuan [1] - The current financing balance of 172 million yuan is above the 90th percentile of the past year, indicating a high level of financing activity [1] Shareholder and Financial Performance - As of September 30, Aojing Medical had 9,862 shareholders, an increase of 15.44% from the previous period, while the average circulating shares per person decreased by 13.37% to 13,892 shares [2] - For the period from January to September 2025, Aojing Medical reported a revenue of 156 million yuan, a year-on-year increase of 5.22%, and a net profit attributable to shareholders of 13.94 million yuan, reflecting a significant year-on-year growth of 185.19% [2] Dividend and Institutional Holdings - Since its A-share listing, Aojing Medical has distributed a total of 58.67 million yuan in dividends, with 22.40 million yuan distributed over the past three years [3] - As of September 30, 2025, the eighth largest circulating shareholder is Rongtong Health Industry Flexible Allocation Mixed A/B, holding 2.40 million shares as a new shareholder [3]

Core Insights - The 24th Chinese Orthopaedic Association (COA) conference showcased significant advancements in orthopedic technology, emphasizing the integration of robotics, navigation, imaging, and biomaterials under the theme "Digital Intelligence in Orthopedics" [2] - The conference attracted 20,188 registered participants and received 37,222 submissions, indicating a strong interest in orthopedic innovations [2] Group 1: Robotics and Navigation Systems - Surgical robots and navigation systems are expanding across various orthopedic fields, moving beyond joint surgeries to include spine, trauma, and sports medicine, focusing on precision and standardization [4] - Companies like Stryker, Tianzhihang, and others are presenting comprehensive orthopedic platforms that integrate imaging, navigation, and robotic arms, forming a closed-loop system for enhanced surgical outcomes [4] - The Trinity system by Tuo Dao Medical demonstrates a unified platform for rapid switching between surgical procedures, showcasing advancements in AI planning and real-time navigation [19] Group 2: Biomaterials and Bone Repair - The competition in bone repair and biomaterials is intensifying, with companies offering innovative solutions such as absorbable screws and 3D-printed bioceramics, focusing on osteogenic activity and infection resistance [4] - Smartbone and other manufacturers are introducing advanced materials that not only fill defects but also promote bone regeneration and integration [4] Group 3: Domestic Innovations - Domestic companies are accelerating the development of high-end joint prosthetics and key materials, with a focus on integrating materials, prosthetic design, and manufacturing processes [4] - The collaboration between local firms and international companies is shifting from product showcases to establishing standards and ecosystems, enhancing the overall orthopedic landscape [4] Group 4: Key Product Launches - Stryker highlighted its latest products, including the Mako robotic system, which integrates multiple surgical techniques for hip and knee replacements, enhancing precision and efficiency [5][7] - Rosenboht signed a strategic partnership with the Chinese University of Hong Kong to advance intelligent surgical technologies, aiming for more precise and minimally invasive orthopedic procedures [12][14] - The launch of the "Panshi Self-Pressing 3D Partition Bone Trabecular Biological Knee Prosthesis" by Jiashite Medical showcases advancements in mechanical stability and biological fixation [40][42] Group 5: Technological Integration - Companies are increasingly focusing on integrating AI and imaging technologies to enhance surgical precision and safety, as seen in the solutions presented by Meiya Optical and other firms [46][50] - The introduction of AR navigation systems by Linyan Medical represents a significant technological advancement, improving the visibility and accuracy of spinal surgeries [53][55] Group 6: Comprehensive Solutions - The conference highlighted the importance of comprehensive solutions that encompass preoperative planning, intraoperative guidance, and postoperative evaluation, as demonstrated by various exhibitors [4][60] - Companies like Weigao and others are showcasing integrated solutions that leverage digital technologies to enhance the entire orthopedic treatment process [100][102]

证券代码：688613 证券简称：奥精医疗 奥精医疗科技股份有限公司 2025 年第三次临时股东大会 会议资料 二〇二五年十一月 | | | | 2025 | 年第三次临时股东大会会议须知 | 1 | | --- | --- | --- | | 2025 | 年第三次临时股东大会会议议程 | 3 | | 2025 | 年第三次临时股东大会会议议案 | 5 | 奥精医疗科技股份有限公司 2025 年第三次临时股东大会会议须知 为维护广大投资者的合法权益，保障股东在本次股东大会期间依法行使权利， 确保股东大会的正常秩序和议事效率，根据《公司法》《证券法》《上市公司股 东大会规则》《奥精医疗科技股份有限公司章程》《奥精医疗科技股份有限公司 股东大会议事规则》等有关规定，特制定本会议须知： 一、为保证本次大会的严肃性和正常秩序，除出席会议的股东、董事、监事、 高级管理人员、公司聘任律师及中介机构外，公司有权依法拒绝其他人员入场。 二、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 三、请出席大会的股东或其代理人或其他出席者在会议召开前 ...

Core Points - The company has decided to cancel its supervisory board and increase its registered capital, along with revising its articles of association and governance systems to comply with new regulations [1][3][4] Group 1: Cancellation of Supervisory Board - The company will no longer have a supervisory board or supervisors, with the audit committee of the board taking over the supervisory functions as per the Company Law [1][2] - The relevant rules regarding the supervisory board will be abolished, and corresponding amendments will be made to the articles of association [1][2] Group 2: Increase in Registered Capital - The company has completed the registration of shares for the second vesting period of its 2023 restricted stock incentive plan, resulting in an increase in share capital by RMB 1,457,000 and capital reserve by RMB 13,248,486.43 [3] - The total share capital will change from 135,551,584 shares to 137,008,584 shares, and the registered capital will increase from RMB 135,551,584 to RMB 137,008,584 [3] Group 3: Revision of Articles of Association - The company plans to amend its articles of association to enhance governance structure in line with the new regulations and its strategic development needs [4][5] - The definition of senior management will be adjusted by removing the "Chief Scientist" position, thus changing the definition of senior management to include only the General Manager, Deputy General Managers, Board Secretary, and Financial Officer [4][5] - Numerous amendments will be made to the articles of association, including the uniform change of "Shareholders' Meeting" to "Shareholders' Assembly" and the removal of all references to the supervisory board [5]

Group 1 - Huayang Intelligent's shareholder, Fosun Weiying, plans to reduce its stake by up to 285.42 million shares, representing no more than 5% of the company [1] - Kangtai Biological's controlling shareholder's concerted actor, Du Xinglian, intends to reduce its stake by up to 272.4 million shares, which is no more than 0.24% of the total share capital [2] - Mindray Medical has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [4] Group 2 - Junpu Intelligent's chairman, Liu Yuan, resigned for personal reasons, and Wang Jianfeng was elected as the new chairman [6] - Mingchen Health's actual controller and executives plan to collectively reduce their stake by up to 8.61 million shares, accounting for 3.27% of the total share capital [7] - Zhongheng Design's directors and executives plan to reduce their stake by up to 151.57 million shares, representing no more than 0.55% of the total share capital [9] Group 3 - ST Erya and its actual controller, Zheng Jiping, are still under investigation by the China Securities Regulatory Commission [10] - Qicai Chemical's shareholder, Beijing Fengyan, plans to reduce its stake by up to 399.12 million shares, accounting for 0.98% of the total share capital [11] - Aier Eye Hospital plans to distribute a cash dividend of 0.8 yuan per 10 shares to all shareholders, totaling approximately 744 million yuan [12] Group 4 - Meiri Interactive's actual controller's concerted actor plans to reduce its stake by up to 394.74 million shares, which is 1% of the total share capital [13] - Maipu Medical's pre-IPO shareholder plans to reduce its stake by up to 67.05 million shares, representing no more than 1% of the total share capital [15] - Qinchuan Machine Tool's subsidiary plans to increase its registered capital from 50 million yuan to 200 million yuan, introducing new investors [17] Group 5 - Guiyang Bank's proposed director, Yu Rui, has resigned due to work reasons [19] - Guiyang Bank plans to acquire Xifeng Development Village Bank and establish a branch [20] - Aojing Medical's directors and executives plan to collectively reduce their stake by up to 25.28 million shares, accounting for no more than 0.19% of the total share capital [21] Group 6 - Zhongji Xuchuang intends to issue H-shares and list on the Hong Kong Stock Exchange [22] - ST Huatuo's stock will have its risk warning lifted, changing its name to Shiji Huatuo [25] - *ST Gaohong's stock has been delisted from the Shenzhen Stock Exchange [27] Group 7 - Tianwo Technology plans to publicly transfer a 7.12% stake in Qinghai Haihe Railway Transportation Co., with an assessed value of approximately 8.54 million yuan [28] - Xingye Technology's major shareholder plans to reduce its stake by up to 886.65 million shares, representing no more than 3% of the total share capital [29] - Jiangnan Chemical has successfully acquired 100% equity of Chongqing Shun'an Explosive Materials Co., with a transfer base price of 1 billion yuan [31]